Researchers from the Center for Stem Cell Biology and Regenerative Medicine and the Department of Medicine at Thomas Jefferson University claim that a gene shown to play a role in the aging process appears to play a role in the regulation of the differentiation of embryonic stem cells.
In the study, published online in the journal Aging Cell, the researchers identified a protein interaction that controls the silencing of Oct4, a key transcription factor that is critical to ensuring that embryonic stem cells remain pluripotent. The protein, WRNp, is the product of a gene associated with Werner syndrome, an autosomal
Kim and Jay Case with their dog, Shiloh, at Citizen's Lake Campground in Monmouth on Wednesday morning. Kim won her battle with cancer because of an adult stem cell transplant
When Kim Case was diagnosed with a rare form of cancer, doctors told her she had little chance of survival.
Months later when she was recovering from the disease, they changed their tune.
“The doctors called me their miracle patient,” Case said.
Case, who lives in Gaston, Ore. with her husband, Jay — who’s originally from Monmouth — was diagnosed in August 2004 with a rare form of cancer called NK T-cell
Image via Wikipedia
Somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs) by defined factors. However, the low efficiency and slow kinetics of the reprogramming process have hampered progress with this technology. Here we report that a natural compound, vitamin C (Vc), enhances iPSC generation from both mouse and human somatic cells. Vc acts at least in part by alleviating cell senescence, a recently identified roadblock for reprogramming.
In addition, Vc accelerates gene expression changes and promotes the transition of pre-iPSC colonies to a fully reprogrammed state. Our results therefore highlight a straightforward method for improving the speed and
Currently stem cell research is only a hope and a strong one at that, and Obama was right to resume a promising line of research that could also be useful for multiple sclerosis. This was a statement made by 1986 Nobel Prize for medicine winner Rita Levi Montalcini who spoke yesterday morning at a conference sponsored by Italian MS Society (AISM), of which she was Honorary President for the First World Multiple Sclerosis Day.
“Embryonic stem cell research is only one of the paths we are taking, and although we are far away, we must never surrender. I am certain
Alan Lewis of the Juvenile Diabetes Research Foundation distinguishes type 1 and type 2 diabetes, and continues to explain how stem cells are being used today to develop new treatments for type 1 diabetes (a.k.a. juvenile diabetes). Human embryonic stem cells (hESC) are being differentiated to the beta (insulin producing) cells that type 1 diabetics lack, and are being transplanted , in animal models. Since type 1 diabetes is an auto-immune disease, the transplanted cells must be protect from destruction by the immune system. Currently, researchers are working towards that goal with encapsulating technologies and a “gentle” immuno-modulation. In